2 years ago

GenoME Diagnostics Secures €1.5 Million to Improve Ovarian Cancer Diagnosis

  • GenoME Diagnostics, a Belfast-based startup developing a solution for earlier and more accurate detection of ovarian cancer, has secured over €1.5 million (£1.4 million) in funding

  • The investment will be used to expand the company's operations, complete lab testing, file for regulatory approval in the EU, expand its regulatory approach to the UK and North America, and continue research development

  • GenoME Diagnostics' lead product, OvaME, offers a novel blood test for earlier and more accurate detection of ovarian cancer

  • The company plans to extend the technology to additional cancer types.

      • ProblemHealthcare

      "Cancer diagnosis is often late, which reduces the chance of survival and improves the quality of life."

      Solution

      "GenoME Diagnostics has developed a faster and more accurate blood test for earlier detection of ovarian cancer, and plans to extend the technology to diagnose other cancers and illnesses."

      Covered on